Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance - Turner, David C.; Kondic, Anna G.; Anderson, Keaven M.; Robinson, Andrew G.; Garon, Edward B.; Riess, Jonathan Wesley; Jain, Lokesh; Mayawala, Kapil; Kang, Jiannan; Ebbinghaus, Scot W.; Sinha, Vikram; de Alwis, Dinesh P.; et al. (Clinical cancer research, 2018)
Keywords: Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Cachexia - etiology; Cachexia - metabolism; Cachexia - mortality; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Case-Control Studies; Humans; Kaplan-Meier Estimate; Melanoma - complications; Melanoma - drug therapy; Neoplasms - complications; Neoplasms - drug therapy; Neoplasms - mortality; Proportional Hazards Models; Randomized Controlled Trials as Topic